C'tee finds no irregularities Teva’s Hurwitz death

Teva Pharmaceuticals’ industrialist Eli Hurwitz's family had lodged complaints about his treatment at Sheba.

August 1, 2012 03:12
2 minute read.
Eli Hurwitz

Eli Hurwitz 370. (photo credit: Wikimedia Commons / CC)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

A committee appointed by the Health Ministry to investigate complaints by the family of the late Teva Pharmaceuticals’ industrialist Eli Hurwitz against Sheba Medical Center, where he died of cancer last year stated on Tuesday that there were no irregularities in his care.

“The medical treatment he received was carried out according to acceptable standards,” the committee – headed by ministry medical complaints commissioner Prof. Chaim Hershko said.

Be the first to know - Join our Facebook page.

The committee said that the government hospital’s medical team in general, both doctors and nurses, “did not properly assess the seriousness of Hurwitz’s condition and thus communicated to his family a too-optimistic assessment.”

Some of the family’s complaints resulted from the gap between their expectations and the reality of his condition.

There was a need to better update the family on the seriousness of his prognosis, the committee said, adding that it was vital to remind the medical teams of the importance of matching the expectations of the family and the prognosis.

Hershko and his colleagues said that the role of the doctor in charge of the shift to respond to queries by the patient and his family should be set down clearly.

They found that results of blood tests taken one day were not made known to the doctors; this requires a new assessment of work habits.

The committee said that the case reflected the severe crowding and overwork in internal medicine departments and the lack doctors, nurses and intensive care beds. Despite this criticism, the committee said Hurwitz’s medical care was properly given.

Sheba management in Tel Hashomer said it accepted the recommendations made by the committee, including the need to improve communications between the patient and his family on the one hand and the medical team on the other. It will also revise work practices in the hospital’s departments. The hospital called on the Health Ministry to increase significantly the number of beds in internal medicine departments and manpower in intensive care units of public medical centers.

The hospital’s management, however, protested against the “gap” between the committee’s conclusions that the industrialist received acceptable treatment and its comments about the “weakness” of work practices in the department.

Hospital director-general Prof. Zeev Rotstein sent his condolences to the family and expressed his appreciation of Hurwitz, who was a Sheba supporter, but said it was unlikely that if an earlier assessment of his condition would have changed the unfortunate end result.”

Related Content

August 31, 2014
Weizmann scientists bring nature back to artificially selected lab mice